Low pretreatment total testosterone (<3 ng/mL) predicts extraprostatic disease in prostatectomy specimens from patients with preoperative localized prostate cancer

BJU International

Volumn 107, Issue 9, 2011, Pages 1400-1403

  Xylinas, Evanguelos ^a   Ploussard, Guillaume ^a   Durand, Xavier ^a   Fabre, Alban ^a   Salomon, Laurent ^a   Allory, Yves ^a   Vordos, Dimitri ^a   Hoznek, Andras ^a   Abbou, Claude Clément ^a   De La Taille, Alexandre ^a  

^a HENRI MONDOR HOSPITAL   (France)

Author keywords

localized; prostate neoplasms; prostatectomy; testosterone

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; TESTOSTERONE;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; BODY MASS; CANCER STAGING; CANCER SURVIVAL; CARDIOVASCULAR DISEASE; COHORT ANALYSIS; COMORBIDITY; DIABETES MELLITUS; DIGITAL RECTAL EXAMINATION; GLEASON SCORE; HISTOPATHOLOGY; HUMAN; LAPAROSCOPY; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PREDICTION; PREOPERATIVE EVALUATION; PREOPERATIVE PERIOD; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE DISEASE; PROSTATECTOMY; RISK FACTOR; TESTOSTERONE BLOOD LEVEL;

AGED; EPIDEMIOLOGIC METHODS; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS; PROSTATECTOMY; PROSTATIC NEOPLASMS; TESTOSTERONE; TUMOR MARKERS, BIOLOGICAL;

EID: 79955459178     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2010.09816.x     Document Type: Article

References (22)

1. Chodak GW, Vogelzang NJ, Caplan RJ, Soloway M, Smith JA,. Independent prognostic factors in patients with metastatic (stage D2) prostate cancer. The Zoladex Study Group. JAMA 1991; 265: 2808
2. Ribeiro M, Ruff P, Falkson G,. Low serum testosterone and a younger age predict for a poor outcome in metastatic prostate cancer. Am J Clin Oncol 1997; 20: 605-8 (Pubitemid 27509888)
3. Partin AW, Kattan MW, Subong EN, et al,. Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update. JAMA 1997; 277: 1445-51 (Pubitemid 27208886)
4. Lu-Yao GL, Potosky AL, Albertsen PC, Wasson JH, Barry MJ, Wennberg JE,. Follow-up prostate cancer treatments after radical prostatectomy: a population-based study. J Natl Cancer Inst 1996; 88: 166-73 (Pubitemid 26065828)
5. Huggins C, Stevens RE, Hodges CV,. Studies on prostatic cancer: II. The effects of castration on advanced carcinoma of the prostate gland. Arch Surg 1941; 43: 209
6. English HF, Kloszewski ED, Valentine EG, Santen RJ,. Proliferative response of the Dunning R3327H experimental model of prostatic adenocarcinoma to conditions of androgen depletion and repletion. Cancer Res 1986; 46: 839-44 (Pubitemid 16145446)
7. Sheth AR, Garde SV, Mehta MK, Shah MG,. Hormonal modulation of biosynthesis of prostatic specific antigen, prostate specific acid phosphatase and prostatic inhibin peptide. Indian J Exp Biol 1992; 30: 157-61
8. Chen SS, Chen KK, Lin AT, et al,. The correlation between pretreatment serum hormone levels and treatment outcome for patients with prostatic cancer and bony metastasis. BJU Int 2002; 89: 710-5
9. Iversen P, Rasmussen F, Christensen IJ,. Serum testosterone as a prognostic factor in patients with advanced prostatic carcinoma. Scand J Urol Nephrol 1994; 157: 41-5
10. Morgentaler A, Rhoden EL,. Prevalence of prostate cancer among hypogonadal men with prostate-specific antigen levels of 4.0 ng/mL or less. Urology 2006; 68: 1263-7 (Pubitemid 44880344)
11. Yamamoto S, Yonese J, Kawakami S, et al,. Preoperative serum testosterone level as an independent predictor of treatment failure following radical prostatectomy. Eur Urol 2007; 52: 696-701 (Pubitemid 47126163)
12. Hoffman MA, DeWolf WC, Morgentaler A,. Is low serum free testosterone a marker for high grade prostate cancer? J Urol 2000; 163: 824-7 (Pubitemid 30091624)
13. Schatzl G, Madersbacher S, Haitel A, et al,. Associations of serum testosterone with microvessel density, androgen receptor density and androgen receptor gene polymorphism in prostate cancer. J Urol 2003; 169: 1312-6
14. Massengill JC, Sun L, Moul JW, Wu H, et al,. Pretreatment total testosterone level predicts pathological stage in patients with localized prostate cancer treated with radical prostatectomy. J Urol 2003; 169: 1670-5 (Pubitemid 36443468)
15. Imamoto T, Suzuki H, Akakura K, et al,. Pretreatment serum level of testosterone as a prognostic factor in Japanese men with hormonally treated stage D2 prostate cancer. Endocr J 2001; 48: 573-9
16. Isom-Batz G, Bianco FJ Jr, Kattan MW, Mulhall JP, Lilja H, Eastham JA,. Testosterone as a predictor of pathological stage in clinically localized prostate cancer. J Urol 2005; 173: 1935-7 (Pubitemid 40675215)
17. Teloken C, Da Ros CT, Caraver F, Weber FA, Cavalheiro AP, Graziottin TM,. Low serum testosterone levels are associated with positive surgical margins in radical retropubic prostatectomy: hypogonadism represents bad prognosis in prostate cancer. J Urol 2005; 174: 2178-80 (Pubitemid 41611769)
18. Thompson IM, Goodman PJ, Tangen CM, et al,. The influence of finasteride on the development of prostate cancer. N Engl J Med 2003; 349: 215-20 (Pubitemid 37021457)
19. Scardino PT,. The prevention of prostate cancer-the dilemma continues. N Engl J Med 2003; 349: 297-302
20. Morgentaler A, Bruning CO, DeWolf WC,. Occult prostate cancer in men with low serum testosterone levels. JAMA 1996; 276: 1904-8
21. Zhang PL, Rosen S, Veeramachaneni R, Kao J, DeWolf WC, Bubley G,. Association between prostate cancer and serum testosterone levels. Prostate 2002; 53: 179-82 (Pubitemid 35266177)
22. Miller LR, Partin AW, Chan DW, et al,. Influence of radical prostatectomy on serum hormone levels. J Urol 1998; 160: 449-53 (Pubitemid 29476696)